Scientific Advisory Board


Jagannadha K. Sastry, Ph.D.

Professor, MD Anderson Cancer Centre, Houston, USA

aProf Sastry has dual positions at the MD Anderson Cancer Centre, Texas.  His primary position is of the Professor at the Department of Immunology, and the second position is of the Professor at the Department of Veterinary Sciences.  He did his PhD at the National Dairy Research Institute, India then his post-doctoral studies at the Purdue University and then at the University of Texas.

His research is primarily focused on viral oncology and immunology, and intersects different disciplines such as biology, pathology, immunology, and genetics of two viral diseases impacting human health: human immunodeficiency virus (HIV) infection that causes acquired immunodeficiency syndrome (AIDS) and human papillomavirus (HPV) infection associated with genital cancers like the cervical cancer and others like the oropharyngeal cancers. He has worked on development of procedures and reagents for prediction, treatment as well as prevention of these human infectious immune disorders. The ongoing projects are synthetic peptide-based vaccines and therapeutics that offer the advantage of being defined, safe and economical.



Prof. Dileep Mavlankar

Director, IIPH-Gandhinagar

bDr Mavlankar has a Doctorate of Public Health from the Johns Hopkins University, USA. He then worked as a post-doctoral fellow at the National Institute of Health (NIH) in USA. He was a Senior Management Advisor to the Averting Maternal Mortality and Morbidity (AMDD) program of Mailman School of Public Health, Columbia University, New York. His areas of interest include management of Maternal Health programs and health systems improvement, quality of care, reproductive healthcare, and management of services.  Dr Mavlankar has published several articles in professional journals, book chapters and working papers, and has developed courses on services management & health and hospital management for graduate students.

Dr Mavlankar is a consultant to several international organizations including Columbia University, WHO, UNICEF, CARE, Aga Khan Foundation, UNDP/World Bank and government of India’s health and family welfare departments and state governments.  He has been a member of several programme & scientific advisory committees including GAVI Switzerland, MotherCare project USA, NIHFW, New Delhi, IIPS, Mumbai, IIHMR Jaipur, IMMPAC Project University of Aberdeen UK, etc.  He was appointed by the Prime Minister to the Missions Steering Group of the National Rural Health Mission constituted by the Government of India.


Dr. Bharat Chattoo

Distinguished Professor, MS University at Baroda

cProf Chattoo is a Distinguished Professor with the Department of Microbiology and Biotechnology Centre, M.S. University of Baroda, Baroda. He has been the Head of the Department of Microbiology, M.S. University of Baroda, (1996-2001) and has been a professor since 1986. He is the Coordinator of Biotechnology Teaching Programme and the Director of Centre for Genome Research at M.S. University and is the founder Vice Chancellor of the Shri Mata Vaishno Devi University, Jammu.

Dr. Chattoo received his Ph.D. from the University of Delhi, with a thesis in the field of Microbial Genetics. Subsequently, he worked at the University of Rochester Medical Centre in the area of yeast molecular genetics. He has been a Visiting Scientist/Professor, at the Weizmann Institute of Science, Israel, National Institute of Bioscience and Human Technology, Tsukuba, Japan, Rice Genome Programme, Tsukuba, Japan & United States Department of Agriculture, Beltsville, Maryland.

Prof Chattoo has worked at the Sarabhai Research Centre, Baroda and served as chairman Centre of Biosciences, University of Roorkee. He was on staff as a scientist at the Centre for Cellular & Molecular Biology, Hyderabad, and also worked at the Friedrich Miescher Institute, Switzerland.

Prof Chattoo is a fellow of the Indian National Science Academy, National Academy of Agricultural Sciences National Academy of Sciences (Allahabad)Third World Academy of Sciences (TWAS) and Guha Research Conference He serves on several expert committees of the Government of India and is a member of the task force of the Department of Biotechnology, Govt. of India and Gujarat Biotechnology Council of Government of Gujarat. He received the national technology award for transfer of technology to industry and he is a recipient of the Acharya J C Bose National Fellowship of DST.

Prof Chattoo is currently heading Biotech Cluster Innovation Centre and Genomics Research Centre, both at Maharaja Sayaji University at Baroda, Vadodara, Gujarat.


Dr Venkat Mukku

President, Global Cellular & Analytic Solutions

eDr. Venkat Mukku is a Biochemist and Cell Biologist with experience of over 25 years in biotech industry, both in technical and leadership roles. He has to his credit over 50 peers reviewed publications and two biotech patents.

He holds a Ph. D. degree in Biochemistry from IISC, Bangalore and two Post Doctorals from National Cancer Institute, NIH, Bethesda, MD and University of Texas Medical School, Houston, TX.

He started his career with Genentech Inc. as a scientist and later worked in the capacity of Group Leader. In Genetech Inc. he directed a group comprising 26 staff members (7 Ph.D level scientists). His responsibilities included budgeting, annual performance reviews, staff career development and development of strategic initiatives. He contributed to alignment of Best Practices and development of guidelines for analytical method qualification/validation. He Participated in Due Diligence site visits for In-Licensing and provided expert opinion and scientific support in patent litigation and intellectual property protection.

He is an elected member of USP Biologics and Biotechnology Expert Committee (2005-2010 term) and elected member of USP Biologics and Biotechnology Monographs-1 Expert Committee (2010-2015 term). He is also a member of American Association of Pharmaceutical Scientists (AAPS). He has Co-Chaired three Antibody World Summits during 2003-2006.

Currently he is President of Global Cellular & Analytic Solutions, California, USA.


Mr Mani Iyer

Founder & Director, Incube Ventures

d2Mani Iyer’s inordinate zeal for science, research and innovation made him to purse Post Graduation in Science from St. Stephens College, University of Delhi. Later, as a successful career professional, scientist and researcher he had a wonderful stint with India’s top medical and pharmaceutical research based companies

Mani Iyer headed a major bio therapeutics initiative (including a successful bio-generic programme with a global focus in terms of product development) and contributed to strategic planning for business expansion and diversification. He also managed Intas Biopharmaceuticals (IBPL) that had many r- DNA therapeutics products in the market including SOE which is now under European trials. During his tenure with IBPL, the company introduced the first generic Pegylated Filgrastim in the country.Mani Iyer’s visible contribution is in bridging innovative research and the realities of the market scenario. For over 20 years, he has been participating, raising capital, investing and mentoring pharmaceutical, clinical, and biological product companies. To name a few, the INTAS Group based in Gujarat, and the LAMBDA Therapeutics, which is one of the early CRO based in India, were nurtured and grown by Mani Iyer.

Mani Iyer is also part of the core group promoting blood banks (PRATHAMA Blood Bank, Ahmedabad). For the first time in India, he pioneered the development of biological products from recovered human plasma sourced from Indian blood banks, and achieved fractionation of the same through contract fractionation at KGCC (Korea ).This helped him to develop a regulatory process and achieve collaboration in modular technology for fractionation.

At present, as the Managing Director of Incube Ventures, Mani Iyer focuses on discovering, identifying, and incubating businesses, technologies, and ideas.


Dr Taslimarif Saiyed

Director & COO, C-CAMP, NCBS

gIn his role as Director and COO,  Dr Saiyed manages C-CAMP’s strategies, operations, and business worldwide. This includes management/promotion of technology facilities, strategic collaborations for new technology creation, education and training programmes, and innovation accelerator unit. Additionally, he also oversees the Intellectual Property Management Office (IPMO) and Technology Transfer Office at C-CAMP.

Prior to joining C-CAMP, Dr Saiyed was based in San Francisco where he was a scientist with University of California, San Francisco (UCSF), working on neurodegenerative diseases like Parkinson’s disease. In the bay area, he also worked as a consultant with QB3 New Biotech Venture Consulting as well as in an individual capacity where he consulted for biotech firms in the US, providing in-depth analysis backed recommendations on market analysis, funding, IP issues, technology transfer, and competitive intelligence. He holds a doctorate in Neuroscience from Max-Planck Institute for Brain Research, Germany.


Dr Kenneth Payie

Founder, KGP-Biotech Consulting LLC

fDr Payie has founded KGP-Biotech Consulting, LLC, which executes cost-effective drug development solutions, and assists virtual companies, small biotechs, and research groups with strategic planning, implementation/execution, project management and lean activities for early-phase assets. Kenneth Payie, PhD, has more than a decade of experience in the biopharmaceutical industry in a variety of research and development positions. With a background in large and small molecule Chemistry Manufacturing & Controls (CM&C) development, virtual drug development experience, and Six Sigma black belt execution, Ken has developed a number of large and small molecule CM&C programs in the Candidate Identification to Phase II space for both large pharma and small drug discovery companies. Ken has designed and directed drug development programs through outsourcing to Asia, Europe and North American vendors, and dramatically reduced costs to develop assets without compromising Quality.